Hannes Oberkofler

Dr. Hannes Oberkofler


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
PWPatrick Weydt
Patrick Weydt
SSSelma M Soyal
Selma M Soyal
CGCinzia Gellera
Cinzia Gellera
SDStefano DiDonato
Stefano DiDonato
CWClaus Weidinger
Claus Weidinger
WPWolfgang Patsch
Wolfgang Patsch
Huntington's disease (HD) is one of the most common autosomal dominant inherited, neurodegenerative disorders. It is characterized by progressive motor, emotional and cognitive dysfunction. In addition metabolic abnormalities such as wasting and altered energy expenditure are increasingly recognized as clinical hallmarks of the disease. HD is caused by an unstable CAG repeat expansion in the HD gene (HTT), localized on chromosome 4p16.3. The number of CAG repeats in the HD gene is the main predictor of disease-onset, but the remaining variation is strongly heritable. Transcriptional dysregulation, mitochondrial dysfunction and enhanced oxidative stress have been implicated in the pathogenesis. Recent studies suggest that PGC-1α, a transcriptional master regulator of mitochondrial biogenesis and metabolism, is defective in HD. A genome wide search for modifier genes of HD age-of-onset had suggested linkage at chromosomal region 4p16-4p15, near the locus of PPARGC1A, the gene coding for PGC-1α. We now present data of 2-loci PPARGC1A block 2 haplotypes, showing an effect upon age-at-onset in 447 unrelated HD patients after statistical consideration of CAG repeat lengths in both HTT alleles. Block 1 haplotypes were not associated with the age-at-onset. Homozygosity for the 'protective' block 2 haplotype was associated with a significant delay in disease onset. To our knowledge this is the first study to show clinically relevant effects of the PGC-1α system on the course of Huntington's disease in humans.

1 February 2006 in Endocrinology
Verified
Journal Article
Open access
PDF file
HOHannes Oberkofler
Hannes Oberkofler
KKKerstin Klein
Kerstin Klein
Thomas FelderThomas Felder
Thomas Felder
FKFranz Krempler
Franz Krempler
WPWolfgang Patsch
Wolfgang Patsch
A role of uncoupling protein 2 (UCP2) as negative modulator of insulin secretion has been suggested, but the transcriptional pathways regulating β-cell UCP2 gene expression have been established in rodents only. We show here that the underlying sequence motifs are not conserved in the human gene and provide evidence for regulatory mechanisms involving the transcriptional cofactor peroxisome proliferator-activated receptor-γ coactivator-1 α (PGC-1α). PGC-1α potentiates thyroid hormone (T3)-mediated transcriptional activation of the human UCP2 gene in INS-1E cells. Two thyroid hormone response elements (TREs) located at −322/−317 (TRE1) and −170/−165 (TRE2) were identified, and mutation of either TRE1 or TRE2 abrogated the stimulatory effect of T3 treatment. Furthermore, two E-box motifs at −911/−906 (E1) and −743/−738 (E2) are involved in the regulation of UCP2 gene expression by sterol regulatory element binding protein isoforms (SREBP)-1a, -1c, and -2. Mutational analysis revealed that the presence of either E1 or E2 is sufficient to mediate activation of UCP2 gene transcription by nuclear active SREBPs. PGC-1α coactivates liver X receptor-mediated expression of SREBP-1c as well as dexamethasone-stimulated SREBP-2 expression in INS-1E cells. These transcriptional responses are antagonized by orphan nuclear receptor short heterodimer partner overexpression, which might explain its positive effects on glucose-stimulated insulin secretion in β-cells overexpressing UCP2. We also provide evidence that despite a lack of sequence homology within the regulatory region, the principal mechanisms regulating UCP2 gene expression are similar in rats and humans, being consistent with a role for UCP2 as a modulator of insulin secretion in humans.

13 May 2010 in Diabetologia
Verified
Journal Article
Closed access
PDF file
HOHannes Oberkofler
Hannes Oberkofler
APA. Pfeifenberger
A. Pfeifenberger
SSS. Soyal
S. Soyal
Thomas FelderThomas Felder
Thomas Felder
PHP. Hahne
P. Hahne
WPW. Patsch
W. Patsch

18 December 2009 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JCJanne Cadamuro
Janne Cadamuro
BDBenjamin Dieplinger
Benjamin Dieplinger
Thomas FelderThomas Felder
Thomas Felder
IKIgor Kedenko
Igor Kedenko
TMThomas Mueller
Thomas Mueller
HOHannes Oberkofler
Hannes Oberkofler

12 December 2006 in International Journal of Obesity
Verified
Journal Article
Closed access
Thomas FelderThomas Felder
Thomas Felder
HOHannes Oberkofler
Hannes Oberkofler
RWR Weitgasser
R Weitgasser
VMVitolds Mackevics
Vitolds Mackevics
FKF Krempler
F Krempler
WPW Patsch
W Patsch

11 December 2008 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
HOHannes Oberkofler
Hannes Oberkofler
MHMichael Hafner
Michael Hafner
Thomas FelderThomas Felder
Thomas Felder
FKFranz Krempler
Franz Krempler
WPWolfgang Patsch
Wolfgang Patsch